ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Oncogene Année : 2007

ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines

J. Adelaiede
  • Fonction : Auteur
L. Repellini
  • Fonction : Auteur
F. Sircoulomb
  • Fonction : Auteur
P. Finetti
J. Geneix
  • Fonction : Auteur
F. Bertucci
P. Viens
  • Fonction : Auteur
D. Birnbaum
  • Fonction : Auteur

Résumé

Breast cancers that overexpress the ERBB2 tyrosine kinase receptor may be treated with the recombinant humanized monoclonal anti-ERBB2 antibody trastuzumab (herceptin). However, resistance to this targeted therapy is frequent. We have determined the response of 18 breast tumor cell lines to trastuzumab and compared it with the ERBB2 phosphorylation status using antibodies directed against tyrosine residue 1248. We show that sensitivity to trastuzumab is frequently associated with the expression of a phosphorylated ERBB2 protein.

Dates et versions

hal-01431967 , version 1 (11-01-2017)

Identifiants

Citer

C. Ginestier, J. Adelaiede, A. Goncalves, L. Repellini, F. Sircoulomb, et al.. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines. Oncogene, 2007, 26 (50), pp.7163-7169. ⟨10.1038/sj.onc.1210528⟩. ⟨hal-01431967⟩
102 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More